280 related articles for article (PubMed ID: 20609386)
1. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients.
Sun HY; Cacciarelli TV; Wagener MM; Singh N
Transpl Immunol; 2010 Aug; 23(4):166-9. PubMed ID: 20609386
[TBL] [Abstract][Full Text] [Related]
2. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
4. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
Lisboa LF; Preiksaitis JK; Humar A; Kumar D
Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
[TBL] [Abstract][Full Text] [Related]
6. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
7. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
Tan SK; Waggoner JJ; Pinsky BA
J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
[TBL] [Abstract][Full Text] [Related]
9. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection.
Martín-Gandul C; Pérez-Romero P; Sánchez M; Bernal G; Suárez G; Sobrino M; Merino L; Cisneros JM; Cordero E;
J Clin Virol; 2013 Jan; 56(1):13-8. PubMed ID: 23131346
[TBL] [Abstract][Full Text] [Related]
10. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
[TBL] [Abstract][Full Text] [Related]
12. Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.
Singh N; Winston DJ; Razonable RR; Marshall Lyon G; Silveira FP; Wagener MM; Limaye AP
J Infect Dis; 2022 Feb; 225(3):436-442. PubMed ID: 33755176
[TBL] [Abstract][Full Text] [Related]
13. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia.
Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S
J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
15. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
[TBL] [Abstract][Full Text] [Related]
16. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2013 May; 57(1):50-3. PubMed ID: 23403239
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
18. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
[TBL] [Abstract][Full Text] [Related]
20. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S
World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]